Celyad Oncology announced on Monday that it is suspending a cancer therapy trial to investigate the deaths of two patients. This is a treatment administered to patients with refractory metastatic colorectal cancer, specifies the Guibertine company in a press release.
She decided “to voluntarily suspend treatment and recruit patients into the study, in order to investigate these two deaths. Celyad Oncology is currently analyzing these two cases and evaluating any other potential similar events in other patients treated in this study.“.
The company’s price was down more than 13% on Monday morning on the Brussels Stock Exchange, following this announcement.
Related posts:
The first trillionaire in history - Al Ain News
Open for reservation Savings deposit, high interest 6.50% per year, final round
The International Monetary Fund provides $7.5 billion to this country
“We built too much and too big”: the State at the bedside of ugly France
Renovation Update: Tangierine Café in EPCOT's Morocco Pavilion Unveils Standing Menu Board and Nejja...
CEMAC: increase in the total balance sheet of banks
Gold prices in Egypt today, Tuesday, February 27, 2024, in evening trading
Fed before a radical step: That means the turnaround in interest rates for investors